| Description |
TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research[1].
|
| Related Catalog |
|
| Target |
TLR7
|
| In Vitro |
TMX-201 is more potent cytokine inducer than Imiquimod (HY-B0180) in both mouse and human mononuclear cells. TMX-201 shows less off-target binding compared to Imiquimod[1].
|
| In Vivo |
The maximum tolerated dose of TMX-201 by i.v. administration is 75 mg/kg[1]. TMX-201 (4mg/kg, IP) suppresses the growth of established subcutaneous B16 melanoma by 46%, without discernible adverse effects[1]. TMX-201 (IP or intra-tumor administration), in combination with anti-CTLA4 antibody, significantly suppressed lung metastasis formation in the 4T1 breast cancer model[1].
|
| References |
[1]. Dennis A. Carson, et al. Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration. Cancer Res 2014;74(19 Suppl): 2568.
|
